Leadership

Ronald D. Guttmann, MD, FRCPC, Vice President, Clinical Development

Dr. Guttmann is Emeritus Professor of Medicine and former Director of the McGill University Centre for Clinical Immunobiology and Transplantation. Dr. Guttmann has been active in the biomedical industry and biotechnology investment consulting since 1985.

Directors

Ronald D. Guttmann, (see above)

Mark Allegretta, PhD, Dr. Allegretta has over 20 years of experience in biotechnology and academic research and development. He received his PhD from the University of Vermont in 1990, and was a post-doctoral fellow at Stanford University School of Medicine. Dr. Allegretta is a co-founder of EndoGen and was most recently associated with Connetics Corporation and InterMune Pharmaceuticals. He is currently Associate Vice President, Research for the National Multiple Sclerosis Society.

Thomas S. Gillespie, B.C.L. Mr. Gillespie is the former President of Tyringham Investments and prior to 2001 he was a Senior Partner of Ogilvy Renault, a major Canadian law firm, where he was a member of the firm’s Executive Committee for ten years. Mr. Gillespie has served as a director or officer of a number of corporations including Volvo Canada, Guerlin Canada, Imperial Tobacco of Canada, and the Daily Mail and General Trust, England.

Partnerships

Our products and technology are developed through collaboration. These valuable connections enable BioMosaics to continue providing cutting edge products and service in the oncology diagnostics market. Our Glypican-3 antibody products were invented by Professor Jorge Filmus PhD, Department of Medical Biophysics, Sunnybrook Health Sciences Centre. Also, we are currently working with the Molecular Imaging Program and the Asian Liver Center at Stanford University for development of our GPC3 antibody-based PET imaging diagnostic test. For more information about our collaborators, visit our Partnerships page.